TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25782065

Group type: EXPERIMENTAL
Intervention: Attentional distraction (listening to music) during a 12-min running test
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Attentional distraction (listening to music) during a 20-min exercise session
Number of subjects: 53

Group type: COMPARATOR
Intervention: No attentional distraction during a 12-min running test
Number of subjects: 53

Group type: COMPARATOR
Intervention: No attentional distraction during a 20-min exercise session
Number of subjects: 53
Study: 23106262

Group type: EXPERIMENTAL
Intervention: Incremental theory intervention (6 sessions)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Coping skills control group
Number of subjects: 230

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 230
Study: 21354368

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125-0.75 mg/d)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 18500518

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg p.o. alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Imatinib 400 mg p.o. with 20 mL antacid (1.6 g Al(OH)(3) + 1.6 g Mg(OH)(2)) 15 min before imatinib
Number of subjects: 12
Study: 17413095

Group type: EXPERIMENTAL
Intervention: Normal calcium intake (1 g/d) during weight loss
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High calcium intake (1.8 g/d) during weight loss
Number of subjects: 44

Group type: COMPARATOR
Intervention: Weight maintenance group (1 g Ca/d)
Number of subjects: 44
Study: 15465449

Group type: EXPERIMENTAL
Intervention: Negative driving phases
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Waxing phases
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall EEG activity
Number of subjects: 14
Study: 12577419

Group type: EXPERIMENTAL
Intervention: Astragalus injection (ASI) 20 ml in 500 ml 5% glucose solution, once a day for 2 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (standard anti-tuberculosis regimen HRE (S)Z or KHZ1321 TH)
Number of subjects: 76
Study: 9701408

Group type: EXPERIMENTAL
Intervention: SR 48968 (100 mg)
Number of subjects: 12
Study: 8055885

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL) beverage
Number of subjects: 0
Study: 2918321

Group type: EXPERIMENTAL
Intervention: Positive frame (probability of survival given)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Negative frame (probability of dying given)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Mixed frame (both probabilities given)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 283
Study: 4615595

Group type: EXPERIMENTAL
Intervention: Ro 7‐0207
Number of subjects: 115

Group type: COMPARATOR
Intervention: metronidazole
Number of subjects: 115
Study: 31897483

Group type: EXPERIMENTAL
Intervention: Multinutrient supplementation (14 g l-arginine, 14 g l-glutamine, 1250 mg vitamin C, 55 mg zinc daily for 14 days before and after surgery)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no multinutrient supplementation)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multinutrient supplementation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 31002583

Group type: COMPARATOR
Intervention: Dapivirine vaginal ring
Number of subjects: 1261
Study: 30098917

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 50
Study: 26902850

Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 24595577

Group type: EXPERIMENTAL
Intervention: TPF50 (traditional physical sunscreens SPF 50, liposome-encapsulated DNA repair enzymes complex, antioxidant complex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing DNA repair and antioxidant and growth factor topical products with SPF 50 sunscreens
Number of subjects: 0
Study: 21733926

Group type: EXPERIMENTAL
Intervention: High-Hb threshold transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-Hb threshold transfusions
Number of subjects: 0
Study: 21221205

Group type: EXPERIMENTAL
Intervention: Timed Suprapubic Cystostomy with Timed Drainage (TSPCD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Continuous Suprapubic Cystostomy with Urine Bag (CSPCD)
Number of subjects: 82
Study: 16643843

Group type: EXPERIMENTAL
Intervention: Penn Resiliency Program (PRP)
Number of subjects: 168
Study: 16243175

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 25
Study: 11834781

Group type: EXPERIMENTAL
Intervention: Opioid analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain-only condition
Number of subjects: 0
Study: 10190764

Group type: EXPERIMENTAL
Intervention: Oramorph SR 30 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: MST-30 Mundipharma Retardtabletten
Number of subjects: 28
Study: 7480610

Group type: EXPERIMENTAL
Intervention: Pilot resource mothers program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Large-scale service program
Number of subjects: 0
Study: 2275325

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with bupivacaine
Number of subjects: 30
Study: 7436160

Group type: EXPERIMENTAL
Intervention: Aerosol metaproterenol (5 puffs, 0.65 mg each, total 3.25 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined regimen (oral metaproterenol 20 mg + aerosol metaproterenol)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral metaproterenol (20 mg tablet)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30901356

Group type: EXPERIMENTAL
Intervention: Vacuum release teat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard teat
Number of subjects: 0
Study: 27864607

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive Coronary Angiography (ICA)
Number of subjects: 0
Study: 25548838

Group type: EXPERIMENTAL
Intervention: Group 1 (strengthening masticatory effort during the denervated atrophic stage)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Group 2 (no instruction to strengthen masticatory effort)
Number of subjects: 98
Study: 23749293

Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate) 240 mg twice daily (BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate) three times daily (TID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20430573

Group type: EXPERIMENTAL
Intervention: Clinical ratings by speech-language pathologists (SLPs)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Laboratory ratings by three experienced SLPs
Number of subjects: 99

Group type: COMPARATOR
Intervention: Median of the three laboratory ratings
Number of subjects: 99
Study: 19221543

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Blended Anesthesia (BA = GA plus epidural analgesia)
Number of subjects: 34
Study: 17374057

Group type: EXPERIMENTAL
Intervention: Cosmetics with active ingredient (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 50
Study: 15533470

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Other treatments
Number of subjects: 100
Study: 11124744

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 20
Study: 9767368

Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg twice daily for 10 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Digitoxin 0.1 mg daily for 10 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8121439

Group type: EXPERIMENTAL
Intervention: HPV DNA detected by polymerase chain reaction (PCR)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Hormonal factors (oral contraceptives and high parity)
Number of subjects: 525
Study: 3113804

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (125 mg, twice daily)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin (250 mg, three times daily)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 93

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin
Number of subjects: 93
Study: 30025748

Group type: EXPERIMENTAL
Intervention: Selective removal (SE)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Stepwise removal (SW)
Number of subjects: 74
Study: 27323167

Group type: EXPERIMENTAL
Intervention: BRS 308 genotype
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1G282 genotype
Number of subjects: 25
Study: 26603245

Group type: EXPERIMENTAL
Intervention: Hydration group (n=17) coached to increase water intake by up to 1.5 L/day for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n=11) asked to maintain regular water intake
Number of subjects: 28
Study: 23659834

Group type: EXPERIMENTAL
Intervention: Hydrotalcite
Number of subjects: 253

Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 253
Study: 16178133

Group type: EXPERIMENTAL
Intervention: 0.075% CPC mouthrinse
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 0.10% CPC mouthrinse
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Number of subjects: 366
Study: 11792655

Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Melatonin 3.0 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10516740

Group type: EXPERIMENTAL
Intervention: Auscultation of Korotkoff sounds inside the cuff
Number of subjects: 151

Group type: COMPARATOR
Intervention: Auscultation of Korotkoff sounds in the antecubital fossa
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Same-arm test in part B
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Opposite-arm test in part B
Number of subjects: 151
Study: 7718752

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 1784882

Group type: EXPERIMENTAL
Intervention: Intravenous regional administration of methylprednisolone (40 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7038051

Group type: COMPARATOR
Intervention: DS103-282
Number of subjects: 0

Group type: COMPARATOR
Intervention: baclofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 30102677

Group type: EXPERIMENTAL
Intervention: α‐HICA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HMB‐FA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HMB‐Ca
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 40
Study: 28726270

Group type: EXPERIMENTAL
Intervention: N2O (nitrous oxide and oxygen)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 64
Study: 26164351

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation intervention including inpatient (20 days) or outpatient (18 days) rehabilitation with follow-up, walking exercises with and without body-weight support, and conventional physiotherapy.
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation intervention
Number of subjects: 147
Study: 22895380

Group type: EXPERIMENTAL
Intervention: 12‐wk supervised exercise program
Number of subjects: 107
Study: 21696894

Group type: EXPERIMENTAL
Intervention: Disulfiram (0, 250, and 500 mg/d, p.o.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol (0.4 g/kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine (30 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg/d, p.o.)
Number of subjects: 0
Study: 17318205

Group type: EXPERIMENTAL
Intervention: AcrySof IOL
Number of subjects: 91

Group type: COMPARATOR
Intervention: EPOCH IOL
Number of subjects: 91
Study: 16505646

Group type: EXPERIMENTAL
Intervention: Low-volume, low-pressure (LVLP) cuff
Number of subjects: 105

Group type: COMPARATOR
Intervention: High-volume, low-pressure (HVLP) cuff
Number of subjects: 105
Study: 12767841

Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated catheters (AIC)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Non-impregnated catheters (non-AIC)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Jugular group catheters
Number of subjects: 390

Group type: COMPARATOR
Intervention: Subclavian group catheters
Number of subjects: 390
Study: 10778866

Group type: EXPERIMENTAL
Intervention: Tyrosine intake at varying levels (3.0, 4.5, 6.0, 7.5, 9.0, 10.5, and 12.0 mg x kg(‐1) x d(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9051817

Group type: EXPERIMENTAL
Intervention: ACD-CPR in standing position (ACD-S)
Number of subjects: 12

Group type: COMPARATOR
Intervention: ACD-CPR in kneeling position (ACD-B)
Number of subjects: 12
Study: 7870903

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (logarithmically increasing doses at 15-min intervals)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 24
Study: 2422994

Group type: EXPERIMENTAL
Intervention: MOPP/ABVD
Number of subjects: 88

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 88
Study: 29972456

Group type: EXPERIMENTAL
Intervention: Selective caries removal (SCR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Complete caries removal (CCR)
Number of subjects: 36
Study: 27515750

Group type: EXPERIMENTAL
Intervention: Short message intervention on good household prenatal practices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short message intervention on healthcare seeking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both short message interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 24417772

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 178

Group type: COMPARATOR
Intervention: Darunavir/ritonavir
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir and darunavir/ritonavir
Number of subjects: 178
Study: 22838229

Group type: EXPERIMENTAL
Intervention: GIC with 10% bioactive glass (group 5)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (group 8)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GIC with 0.01% collagen (group 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GIC with 0.1% collagen (group 3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GIC with 1% collagen (group 4)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GIC with 30% bioactive glass (group 6)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GIC with 50% bioactive glass (group 7)
Number of subjects: 70
Study: 20832282

Group type: EXPERIMENTAL
Intervention: PCEA+AMB (PCEA with AMB of 5 mL every hour)
Number of subjects: 62

Group type: COMPARATOR
Intervention: PCEA+BI (PCEA with basal continuous infusion of 5mL/h)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PCEA+AMB
Number of subjects: 62

Group type: COMPARATOR
Intervention: PCEA+BI
Number of subjects: 62
Study: 18687283

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15925050

Group type: EXPERIMENTAL
Intervention: HMG
Number of subjects: 60

Group type: COMPARATOR
Intervention: rhFSH
Number of subjects: 60
Study: 12933466

Group type: EXPERIMENTAL
Intervention: Single-wall puncture technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional double-wall puncture technique
Number of subjects: 0
Study: 10828010

Group type: EXPERIMENTAL
Intervention: L-asparaginase during consolidation therapy in the medium-risk group (MRG)
Number of subjects: 2178

Group type: COMPARATOR
Intervention: No L-asparaginase during consolidation therapy in the medium-risk group (MRG)
Number of subjects: 2178

Group type: EXPERIMENTAL
Intervention: 12-Gy preventive cranial radiotherapy in the medium-risk group (MRG) and high-risk group (HRG)
Number of subjects: 2178

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen in ALL-BFM 90
Number of subjects: 2178

Group type: EXPERIMENTAL
Intervention: Standard-risk group (SRG) treatment regimen
Number of subjects: 2178

Group type: EXPERIMENTAL
Intervention: Medium-risk group (MRG) treatment regimen
Number of subjects: 2178

Group type: EXPERIMENTAL
Intervention: High-risk group (HRG) treatment regimen
Number of subjects: 2178

Group type: EXPERIMENTAL
Intervention: Overall improvement over results in ALL-BFM 86
Number of subjects: 2178
Study: 8651156

Group type: EXPERIMENTAL
Intervention: 50 mg of meperidine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1 mg of midazolam
Number of subjects: 120
Study: 2000050

Group type: EXPERIMENTAL
Intervention: Active treatment (clonidine plus hydralazine)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 6406198

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) insulin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) insulin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous (i.v.) insulin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 6
Study: 29913072

Group type: EXPERIMENTAL
Intervention: Stream-specific education in pediatrics, women's health, neuro-medical, musculoskeletal, cardiorespiratory, and critical care over 8 weeks (8 hours total)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stream-specific education
Number of subjects: 18
Study: 31002304

Group type: EXPERIMENTAL
Intervention: Engagement with the website's monitoring and feedback component
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Percentage of earned points redeemed for financial incentives
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Frequency of hits on the discussion forum
Number of subjects: 230

Group type: COMPARATOR
Intervention: Identified regulation
Number of subjects: 230

Group type: COMPARATOR
Intervention: Recovery self‐efficacy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Perceived workplace environment safety
Number of subjects: 230

Group type: COMPARATOR
Intervention: EuroQoL health index
Number of subjects: 230

Group type: COMPARATOR
Intervention: Financial motivation
Number of subjects: 230

Group type: COMPARATOR
Intervention: Perceived availability of physical activity opportunities in the workplace environment
Number of subjects: 230
Study: 29078915

Group type: EXPERIMENTAL
Intervention: Mental skills curriculum (MSC) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 27044507

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia at 34 °C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ECLS therapy at normothermia
Number of subjects: 0
Study: 25280869

Group type: EXPERIMENTAL
Intervention: Targeted case finding for COPD
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Active case finding using a postal questionnaire
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Opportunistic-only case finding during routine surgery consultations
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine practice
Number of subjects: 56
Study: 21674765

Group type: EXPERIMENTAL
Intervention: Subclavian catheters
Number of subjects: 83

Group type: COMPARATOR
Intervention: Jugular catheters
Number of subjects: 83
Study: 19180072

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study: 17301565

Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000 gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 24
Study: 15303996

Group type: EXPERIMENTAL
Intervention: Weekly iron supplements (108 mg iron) given for 10 weeks
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Control group (no iron supplements)
Number of subjects: 1510
Study: 11235795

Group type: COMPARATOR
Intervention: Blood alcohol concentration of 0.00%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration of 0.05%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration of 0.08%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prolonged wakefulness (18.5 and 21 hours)
Number of subjects: 18
Study: 10468675

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8580276

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study: 2379634

Group type: EXPERIMENTAL
Intervention: Direct intraperitoneal insemination
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control cycles (same couples)
Number of subjects: 124
Study: 272044

Group type: EXPERIMENTAL
Intervention: Adhesive Restoration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental adhesive fillings in minimally prepared saucer-shaped cavities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other restorative techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enamel conditioning without sealer application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utilization of a sealer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride solution application post-restoration
Number of subjects: 0
Study: 30356327

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26892667

Group type: EXPERIMENTAL
Intervention: Tablet computer
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Interactive voice response system (IVRS)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Paper
Number of subjects: 112